Search research articles

Related Concept Videos

Vaccinations

Vaccinations

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Rh Blood Group

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

Active versus Passive Immunity

Active versus Passive Immunity

Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Healthcare Associated Infections II: Preventive Measures

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Increased Neonatal Vaccine Dose Or Booster Immunization Prevents Hepatitis B Vaccine Breakthrough Infection In Children From Hbsag And Hbeag Positive Mothers.

Home
Increased Neonatal Vaccine Dose Or Booster Immunization Prevents Hepatitis B Vaccine Breakthrough Infection In Children From Hbsag And Hbeag Positive Mothers.

Related Experiment Video

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Increased neonatal vaccine dose or booster immunization prevents hepatitis B vaccine breakthrough infection in

Yuchen Pan^1,2,3, Yanhua Wu¹, Jie Wang^4,5

¹Department of Clinical Epidemiology, the First Hospital of Jilin University, Changchun, China.

|December 4, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Higher hepatitis B vaccine doses and boosters significantly reduce vaccine breakthrough infections in infants born to infected mothers. These strategies help maintain protective antibody levels, lowering infection risk up to age five.

Area of Science:

Immunology
Pediatrics
Public Health

Background:

Infants born to mothers positive for Hepatitis B surface antigen (HBsAg) and e-antigen (HBeAg) face a high risk of Hepatitis B virus (HBV) vaccine breakthrough infection (VBI).
Standard neonatal vaccination protocols may not provide sufficient long-term protection for this high-risk population.

Purpose of the Study:

To evaluate the efficacy of an increased neonatal hepatitis B vaccine dose (20 μg vs. 10 μg) and booster immunization in preventing VBI.
To assess the impact of these strategies on sustained antibody levels (anti-HBs) up to age five.

Main Methods:

A multicenter prospective cohort study involving infants born to HBsAg/HBeAg-positive mothers.
Infants received either a 10 μg or 20 μg neonatal vaccine dose, with some receiving booster immunizations.

Follow-up included monitoring anti-HBs levels and VBI incidence until age five.

Main Results:

The 20 μg neonatal dose group demonstrated higher anti-HBs levels and lower seronegativity rates compared to the 10 μg group.
Booster immunizations effectively increased antibody levels in both dose groups.
VBI incidence was highest in the 10 μg non-booster group, with all infections occurring in non-booster cohorts.

Conclusions:

Increased neonatal hepatitis B vaccine dosage (20 μg) and booster immunization are effective strategies for reducing VBI in high-risk infants.
Combining both strategies offers the lowest VBI risk and promotes sustained anti-HBs immunity.
These findings support optimizing vaccination schedules for infants born to HBsAg/HBeAg-positive mothers.